PRTA Prothena Corporation plc

54.85
-1.38  -2%
Previous Close 56.23
Open 56.75
Price To book 4.30
Market Cap 2.09B
Shares 38,020,000
Volume 130,946
Short Ratio 16.79
Av. Daily Volume 302,211

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 2Q 2017.
PRX002 (PASADENA)
Parkinson's disease
Phase 1b data due 3Q 2017.
PRX003
Psoriatic Arthritis
Phase 3 enrollment to be completed by mid-May 2017.
NEOD001 VITAL
AL Amyloidosis
Phase 2b data due 2Q 2018.
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction

Latest News

  1. Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer
  2. ETFs with exposure to Prothena Corp. Plc : May 15, 2017
  3. Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : May 15, 2017
  4. Prothena Corp. Plc :PRTA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  5. Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View
  6. Prothena reports 1Q loss
  7. Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update
  8. Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : May 4, 2017
  9. Prothena to Report First Quarter 2017 Financial Results on May 9
  10. What to Expect from Prothena (PRTA) This Earnings Season?
  11. Prothena to Participate in the Deutsche Bank 42nd Annual Health Care Conference
  12. Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : April 24, 2017
  13. Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : April 21, 2017
  14. Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : April 6, 2017
  15. Prothena Corporation plc : Press Release
  16. Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease
  17. Don't Let Offerings Blindside Your Thesis